15 results
PRE 14A
HLVX
HilleVax Inc
12 Apr 24
Preliminary proxy
4:05pm
of directors’ significant leadership experience derived from their professional experience and service as executives or board members of other corporations … Health, has served as Executive Director of the UCSF Institute for Global Health Sciences. Prior to UCSF, he was a member of the Foundation Leadership
8-K
EX-99.1
HLVX
HilleVax Inc
20 Mar 24
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
4:05pm
leadership plans. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business
8-K
EX-99.1
HLVX
HilleVax Inc
8 Jan 24
Regulation FD Disclosure
7:05am
with Kangh
Building towards a long-term norovirus vaccine leadership position HIL-216 includes VLPs for six of the most common norovirus genotypes
DEFA14A
67z5wog6734zr5
10 May 23
Additional proxy soliciting materials
4:13pm
8-K
4ghfp008
9 May 23
Departure of Directors or Certain Officers
7:16am
DEF 14A
3je2jjit9xsgzeu9imug
28 Apr 23
Definitive proxy
4:32pm
10-Q
gs95i
8 Jun 22
Quarterly report
4:25pm
424B4
ql1b5
29 Apr 22
Prospectus supplement with pricing info
4:02pm
S-1/A
xxjns l96uas6knr
18 Apr 22
IPO registration (amended)
6:08am
S-1
ifimn0
6 Apr 22
IPO registration
4:21pm
DRS/A
bho 084ke
23 Nov 21
Draft registration statement (amended)
12:00am
DRS
hqe1npogel1fnxma8r
19 Oct 21
Draft registration statement
12:00am
- Prev
- 1
- Next